Arvinas Obtains $41,600,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    395 Winchester Ave. New Haven, CT 06511 USA
  • Company Description
    Arvinas is a pharmaceutical company focused on developing new small molecule strategies aimed at removing unwanted cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds purposes were not disclosed by the company.
  • M&A Terms
  • Venture Investor
    Canaan Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
  • Venture Investor
    RA Capital
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Connecticut Innovations
  • Venture Investor
    Elm Street Ventures

Trending on Xconomy